Control of growth in neuroendocrine gastro-enteropancreatic tumours

This paper reviews data on the effect of pharmacological anti-tumour agents on tumour growth in patients with malignant gastro-enteropancreatic (GEP) tumours. Agents include long-acting somatostatin analogues, interferon-alpha, a combination of both, chemotherapy, and chemo-embolisation. Characteristics of tumours are considered which should be taken into account in the management of patients with metastatic endocrine GEP tumours, including growth rate. Tumour type should be matched to the anti-proliferative strategy.